Articles tagged with Lung Cancer
Researchers report that crizotinib effectively halted tumor growth in 36 of 50 study participants and suppressed it in another 9. The study confirmed that ROS1 is a viable therapeutic target for ROS1-positive lung cancer patients.
A direct comparison of docetaxel and pemetrexed with cisplatin shows similar progression-free survival rates, but docetaxel is associated with more frequent adverse events. The study included 149 patients with non-squamous lung cancer and found that the pemetrexed combination was less toxic.
A substantial proportion of potential subjects are reflexively excluded from lung cancer clinical trials due to prior cancer. The exclusion criterion was applied in more than two-thirds of trials in which survival was not the primary endpoint, resulting in up to 18% exclusion rate.
Researchers found modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy, but no clinically significant cardiac events. The study suggests that longer follow-up and increased dose range may reveal the impact of radiation on late RT-related toxicity.
A new study found that high-risk individuals screened for early-stage lung cancer using low-dose computed tomography (LDCT) can reduce treatment costs by up to 85%, resulting in a significant reduction in mortality rates and improved patient outcomes. The average cost per-person for LDCT screening was $453, while the mean cost for diag...
A new analysis found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions with high rates of histoplasmosis or tuberculosis. Misdiagnosis could lead to unnecessary tests and surgeries, with potential complications and mortality.
A meta-analysis of 70 studies found that fludeoxyglucose F18-PET combined with CT is less accurate for diagnosing lung cancer in areas with endemic infectious lung diseases. The pooled sensitivity was 89%, but specificity was lower (61%) compared to non-endemic regions (77%).
A Yale study found that patients with early-stage non-small cell lung cancer who underwent conventional surgery had better long-term outcomes than those treated with radiosurgery. The study used Medicare billing records of 1,078 patients and found a significant difference in complications and mortality rates between the two groups.
A meta-analysis of 757 Stage IV NSCLC patients found that factors such as timing of metastases and lymph node involvement impact overall survival. The study identified three risk groups with different five-year OS rates, and highlighted the importance of identifying patients who are most likely to benefit from aggressive treatments.
Research found that NSCLC patients who never smoked had a significantly lower risk of developing secondary primary lung cancers (SPLC) compared to current smokers. The study analyzed 1,484 patients and found that five years after diagnosis, current smokers were more likely to develop SPLC.
Researchers present long-term results of RTOG 0236, confirming good primary tumor control and positive 5-year survival rates for patients with inoperable lung cancer. The study found a 40% 5-year survival rate, with seven percent estimated five-year primary tumor failure rate.
A secondary analysis of the National Lung Screening Trial (NLST) data found that both cancer prevalence and positive predictive value of lung cancer screening were higher in the 65+ cohort than in the under-65 cohort. Clinicians should share age-specific estimates of screening benefits and harms with patients to make an informed decision.
Researchers discovered that patients with lung cancer have a higher breath temperature than those without. The study also identified a cut-off value in temperature measurement to accurately diagnose lung cancer.
A combination therapy of two miRNAs, let-7 and miR-34, has been shown to suppress tumor growth in an animal model of non-small-cell lung cancer. The study offers a promising therapeutic avenue for this aggressive malignancy.
Manchester scientists have developed a method to personalize and increase radiotherapy doses for lung cancer patients, potentially improving local control and survival rates. The technique uses intensity modulated radiotherapy (IMRT) to minimize harm to healthy tissue.
Researchers found high concordance (94%) between EGFR mutations in plasma-derived ctDNA and tumor tissue in NSCLC patients. This suggests that a single plasma sample may be sufficient for mutation status assessment when tumor tissue is unavailable.
Researchers found BIM deletion independently predicts overall and progression-free survival in advanced NSCLC patients, particularly in those treated with EGFR TKIs or chemotherapy. The study suggests considering BIM deletion as a clinical trial stratification factor for Asian NSCLC patients.
A large pooled analysis of seven studies involving over 25,000 individuals found associations between lung cancer and chronic bronchitis, emphysema, and pneumonia. Patients with co-occurring chronic bronchitis, emphysema, and pneumonia had a higher risk of lung cancer.
A comprehensive analysis of data from thousands of patients revealed that one in ten cancers would be classified differently using a new classification system based on molecular subtypes. The study provides a more refined, quantitative picture of cancer subtypes and could lead to different treatment options for those patients.
A study of nearly 3,000 cancer survivors found that nearly one in ten continued to smoke many years after diagnosis. The highest rates were seen among bladder and lung cancer patients. Meanwhile, sociodemographic factors such as age, education, and income played a role in smoking status.
A UK psychologist has developed a patient tool to assist with lung cancer screening decision-making, aiming to empower individuals to make informed choices about their health. The tool will provide accurate information and calculate personalized feedback, allowing patients to discuss the decision with their healthcare provider.
Researchers at EPFL discovered that cancer cells with high sugar intake and mobility have a similar mechanism, promoting metastasis and influencing patient survival. The intensity of this phenomenon significantly impacts survival rates, making GLUT3 a potential target for future therapies.
Researchers have found an irreversible inhibitor, SML-8-73-1, that selectively and irreversibly interferes with the activity of mutated KRAS genes. This breakthrough has significant potential to target cancer cells and improve treatment outcomes for patients with lung, pancreas, and colon cancers.
The American College of Radiology (ACR) disputes systemic patient anxiety concerns related to inconclusive cancer screening test results from computed tomography (CT) lung cancer exams. A study by Gareen et al suggests that anxiety effects are minimal, and the lifesaving benefits outweigh any downsides.
Increased use of less toxic chemotherapy treatments in advanced NSCLC is associated with higher overall survival. The study found a significant increase in survival rates among patients receiving second-line therapy, with median overall survival ranging from 3.9 to 11.8 months.
A Vanderbilt University-led team has identified protein 'signatures' of genetic mutations that drive colorectal cancer. The study's findings may lead to new advances in diagnosing and treating the disease by identifying patients who would benefit most from chemotherapy after surgery.
ROS1 gene fusions were detected in 12 out of 492 specimens examined for lung adenocarcinoma using RT-PCR and IHC tests. ROS1 positive patients are significantly younger than the entire population, but there are no associations with gender or smoking history.
Scientists at Salk Institute identify gene DIXDC1 that stops cancer cells from spreading, opening new avenues for treating aggressive lung and other cancers. The discovery provides hope for patients with limited treatment options.
A new 'QTA' technique allows for precise treatment and progress tracking in lung cancer patients with high accuracy. The study found that nearly 90% of tumor cells can be analyzed to detect K-ras gene mutations, enabling personalized treatment.
The US Preventive Services Task Force recommends annual screening for abdominal aortic aneurysms in men aged 65-75 who have ever smoked, while cautioning against widespread lung cancer screening among high-risk older adults due to insufficient evidence. The committee cited age-related risks and diminishing benefits of extended life fro...
A study published in JNCI: Journal of the National Cancer Institute found that a shorter time to first cigarette (TTFC) is associated with an increased risk of lung cancer in both heavy and light smokers. The researchers analyzed data from over 3,200 current and former smokers, revealing that TTFC was statistically significantly higher...
Researchers at UCLA have discovered how factors regulating adult stem cells in lungs can lead to precancerous lesions. The study found that disrupting normal ROS regulation drives repair process, causing precancerous lesions to form.
Researchers develop device that spots lung cancer in exhaled breath, combining novel technologies for early detection and diagnosis. The breathalyzer test uses a nanotech chip to detect unique chemical signatures of lung cancer tumors, accurately distinguishing between benign and malignant lesions.
A systematic review of 8215 studies found that low-dose computed tomography (LDCT) screening does not significantly influence overall quality of life or result in long-term anxiety or distress. However, positive results can lead to short-term increases in distress levels.
A recent study found that a 5-year low-dose computed tomography (LDCT) screening protocol can detect lung cancer effectively, with a high proportion of cancers being treated and good long-term survival rates. The results show improved diagnostic performance compared to other studies, including the National Lung Cancer Screening Trial.
Researchers at Rochester Institute of Technology create algorithms to quantify lung nodule growth on CT scans, identifying small cancers and obviating risky biopsies. The software compensates for background factors and estimates nodule volumes, enabling accurate doubling time calculation and malignant growth detection.
A new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments. The agents deliver two types of payloads directly to cancer cells, resulting in direct imaging or treatment.
A landmark ESMO survey of over 700 specialists provides insight into treatments most oncologists choose for lung cancer patients with incomplete resection. The study reveals that chemotherapy and radiotherapy are commonly prescribed, but treatment decisions vary depending on the specialty of the treating physician.
Researchers have found that crizotinib produces significant responses in patients with intermediate and high MET amplification, resulting in a 60-67% overall objective response rate. The drug showed early activity against MET-dependent cells in preclinical laboratory studies.
A University of Colorado Cancer Center study found NTRK1 mutations in over 1% of non-small cell lung cancer patients. The study also developed a test for rapid detection of NTRK1 oncogenes, marking a new frontier in lung cancer treatment.
A non-invasive breath test has been developed to detect lung cancer by analyzing volatile organic compounds in exhaled breath. The device can distinguish between patients with lung cancer and chronic obstructive pulmonary disease (COPD), as well as define the stage of any present cancer.
A study found that smokers are more likely to quit after receiving a serious lung cancer screening result. The effect appeared to be durable, lasting up to 5 years after the last screening.
A study by Memorial Sloan Kettering Cancer Center found that genomic tumor testing can improve survival for patients with advanced lung cancers. The test identified oncogenic drivers in 64% of tumors, leading to improved outcomes when matched with targeted therapies.
A study found that genetic alterations in lung cancer tumors can help select targeted treatments, resulting in improved survival rates for patients. The researchers identified actionable oncogenic drivers in 64% of patients and used this data to guide treatment decisions.
The study found lung cancer rates declining in 47 of 52 populations among young women (30-49 years), while increasing in most countries among older women (50-74 years). Tobacco control efforts and increased awareness have contributed to the decline, but more needs to be done to curtail future deaths.
A patient diagnosed with advanced, incurable lung cancer was found to have early stage, curable lung cancer after stopping a rare antibiotic that caused liver and lung damage. The team's findings suggest that toxicity due to the antibiotic may be mistaken for cancer spread.
Researchers at Wake Forest Baptist Medical Center have successfully treated patients with recurrent lung cancers using a second course of radiation therapy, achieving a cure rate of over 70%. The innovative treatment approach uses precise targeting and high doses to knock the cancer back, offering new hope for these patients.
A new technique that brings CT imaging into the operating room enables precise demarcation and removal of small sub-centimeter lung nodules while minimizing damage to healthy lung tissue. This approach has shown promising results in reducing errors and increasing accuracy in lung cancer surgery.
A new study using National Cancer Data Base data reveals that major lung resection has become progressively safer over the last few decades. The study found that mortality rates after surgery have decreased, especially at the busiest hospitals with high volumes of surgeries performed.
A new study found that poor global QOL scores do not predict worse survival in high-risk lung cancer patients undergoing sublobar resection, contradicting prior studies. Patients with breathing problems at baseline or decline in function after surgery had poorer overall survival.
Researchers used breath analysis to detect lung cancer with a sensitivity comparable to PET scanning and a higher specificity, distinguishing patients with benign disease from those with early-stage cancer. The method shows promise as a non-invasive diagnostic tool, expediting treatment for patients with lung cancer.
Researchers have discovered that some lung cancers with EGFR gene mutations are uniformly treated throughout the tumor, while others have variable mutation presence. This finding has significant implications for diagnostic accuracy and precision medicine in lung adenocarcinoma.
The EORTC and SIOG have updated their expert opinion on NSCLC management in elderly patients, highlighting the need for personalized treatment decisions based on life expectancy and biological age. Multidisciplinary geriatric assessments can improve treatment outcomes for this population.
A Michigan State University study highlights the emotional toll of lung cancer stigma, with patients feeling guilt, self-blame, and discomfort around healthcare providers. The research aims to raise awareness among healthcare providers and develop strategies to strengthen coping skills and symptom management for affected individuals.
A new study by Mathew S. Isaac and Aaron R. Brough found that people are more likely to predict outcomes when items are grouped into larger categories. In a series of experiments, participants showed a bias towards wagering more money on winning the lottery if they had blue tickets rather than yellow ones.
Researchers at Beth Israel Deaconess Medical Center have identified a key enzyme responsible for lactate production in cancer cells, which they inhibit to halt tumor growth and even cause regression. The study's findings offer promising results for new treatments targeting cancer metabolism.
A study by TGen found that specific growth factor receptors, HGFR/MET and FN14, are elevated in metastatic tumors of non-small cell lung cancer (NSCLC). Suppression of these receptors reduces tumor cell invasion. These findings suggest new targets for therapy to prevent or halt the spread of this deadly cancer.
A phase II trial of efatutazone with erlotinib failed to improve efficacy in patients with refractory non-small cell lung cancer, but researchers hope to refine future treatments by identifying the right biomarker for individual patients. The study found that fluid retention was a key factor contributing to the lack of success.
A meta-analysis of randomized controlled trials found that chemotherapy improved progression-free survival compared to epidermal growth factor receptor tyrosine kinase inhibitors in patients with wild-type EGFR tumors. However, overall survival did not differ between the two groups.
Researchers found that women who underwent radiotherapy for breast cancer have a small but significantly increased risk of developing a primary lung tumour. The risk increases with the amount of radiation absorbed by the tissue, with an estimated relative risk of 8.5% per delivered Gy to the lung.